The CXCL8-CXCR1/2 pathways in cancer

Cytokine and Growth Factor Reviews

Volumn 31, Issue , 2016, Pages 61-71

  Liu, Qian ^a   Li, Anping ^b   Tian, Yijun ^a   Wu, Jennifer D ^c   Liu, Yu ^a   Li, Tengfei ^b   Chen, Yuan ^a   Han, Xinwei ^b   Wu, Kongming ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Angiogenesis; Cancer; CXCL8; CXCR1; CXCR2; Metastasis

Indexed keywords

CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; INTERLEUKIN 8; FOCAL ADHESION KINASE; GUANOSINE TRIPHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; TUMOR MARKER;

ANIMAL; CHEMISTRY; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; ANGIOGENESIS; BREAST CANCER; CANCER PROGNOSIS; CARCINOGENESIS; COLORECTAL CARCINOMA; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; HEMATOLOGIC MALIGNANCY; IMMUNE DEFICIENCY; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; LUNG CANCER; LYMPHOMA; MELANOMA; METASTASIS; NEUTROPHIL; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN STRUCTURE; REVIEW; STOMACH CANCER; SUPPRESSOR CELL; THYROID CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ASSOCIATED NEUTROPHIL; TUMOR IMMUNITY;

ANIMALS; HUMANS; INTERLEUKIN-8; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN CONFORMATION; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, INTERLEUKIN-8B; SIGNAL TRANSDUCTION;

EID: 84994097201     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2016.08.002     Document Type: Review

References (155)

1. [1] Gulumian, M., The role of oxidative stress in diseases caused by mineral dusts and fibres: current status and future of prophylaxis and treatment. Mol. Cell. Biochem. 196 (1999), 69–77.
2. [2] Balkwill, F., Mantovani, A., Inflammation and cancer: back to Virchow. Lancet 357 (2001), 539–545.
3. [3] Waugh, D.J., Wilson, C., The interleukin-8 pathway in cancer. Clin. Cancer Res. 14 (2008), 6735–6741.
4. [4] Hoffmann, E., Dittrich-Breiholz, O., Holtmann, H., Kracht, M., Multiple control of interleukin-8 gene expression. J. Leukoc. Biol. 72 (2002), 847–855.
5. [5] Brat, D.J., Bellail, A.C., Van Meir, E.G., The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol. 7 (2005), 122–133.
6. [6] Araki, S., Omori, Y., Lyn, D., Singh, R.K., Meinbach, D.M., Sandman, Y., et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res. 67 (2007), 6854–6862.
7. [7] Azenshtein, E., Meshel, T., Shina, S., Barak, N., Keydar, I., Ben-Baruch, A., The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors. Cancer Lett. 217 (2005), 73–86.
8. [8] Ferrer, F.A., Miller, L.J., Andrawis, R.I., Kurtzman, S.H., Albertsen, P.C., Laudone, V.P., et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 51 (1998), 161–167.
9. [9] Kim, S.J., Uehara, H., Karashima, T., McCarty, M., Shih, N., Fidler, I.J., Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 3 (2001), 33–42.
10. [10] Shi, Z., Yang, W.M., Chen, L.P., Yang, D.H., Zhou, Q., Zhu, J., et al. Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production. Breast Cancer Res. Treat. 135 (2012), 737–747.
11. [11] Wilson, C., Wilson, T., Johnston, P.G., Longley, D.B., Waugh, D.J., Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol. Cancer Ther. 7 (2008), 2649–2661.
12. [12] Pine, S.R., Mechanic, L.E., Enewold, L., Chaturvedi, A.K., Katki, H.A., Zheng, Y.L., et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J. Natl. Cancer Inst. 103 (2011), 1112–1122.
13. [13] Balasoiu, M., Balasoiu, A.T., Mogoanta, S.S., Barbalan, A., Stepan, A.E., Ciurea, R.N., et al. Serum and tumor microenvironment IL-8 values in different stages of colorectal cancer. Rom. J. Morphol. Embryol. 55 (2014), 575–578.
14. [14] Matsushima, K., Baldwin, E.T., Mukaida, N., Interleukin-8 and MCAF: novel leukocyte recruitment and activating cytokines. Chem. Immunol. 51 (1992), 236–265.
15. [15] Modi, W.S., Dean, M., Seuanez, H.N., Mukaida, N., Matsushima, K., O'Brien, S.J., Monocyte-derived neutrophil chemotactic factor (MDNCF/IL-8) resides in a gene cluster along with several other members of the platelet factor 4 gene superfamily. Hum. Genet. 84 (1990), 185–187.
16. [16] Skelton, N.J., Quan, C., Reilly, D., Lowman, H., Structure of a CXC chemokine-receptor fragment in complex with interleukin-8. Structure 7 (1999), 157–168.
17. [17] Park, S.H., Das, B.B., Casagrande, F., Tian, Y., Nothnagel, H.J., Chu, M., et al. Structure of the chemokine receptor CXCR1 in phospholipid bilayers. Nature 491 (2012), 779–783.
18. [18] Ahuja, S.K., Ozcelik, T., Milatovitch, A., Francke, U., Murphy, P.M., Molecular evolution of the human interleukin-8 receptor gene cluster. Nat. Genet. 2 (1992), 31–36.
19. [19] Matsuo, Y., Raimondo, M., Woodward, T.A., Wallace, M.B., Gill, K.R., Tong, Z., et al. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int. J. Cancer 125 (2009), 1027–1037.
20. [20] Chuntharapai, A., Lee, J., Hebert, C.A., Kim, K.J., Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes. J. Immunol. 153 (1994), 5682–5688.
21. [21] Knall, C., Worthen, G.S., Johnson, G.L., Interleukin 8-stimulated phosphatidylinositol-3-kinase activity regulates the migration of human neutrophils independent of extracellular signal-regulated kinase and p38 mitogen-activated protein kinases. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 3052–3057.
22. [22] Cheng, G.Z., Park, S., Shu, S., He, L., Kong, W., Zhang, W., et al. Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr. Cancer Drug Targets 8 (2008), 2–6.
23. [23] MacManus, C.F., Pettigrew, J., Seaton, A., Wilson, C., Maxwell, P.J., Berlingeri, S., et al. Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells. Mol. Cancer Res. 5 (2007), 737–748.
24. [24] Venkatakrishnan, G., Salgia, R., Groopman, J.E., Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J. Biol. Chem. 275 (2000), 6868–6875.
25. [25] Luppi, F., Longo, A.M., de Boer, W.I., Rabe, K.F., Hiemstra, P.S., Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer 56 (2007), 25–33.
26. [26] Knall, C., Young, S., Nick, J.A., Buhl, A.M., Worthen, G.S., Johnson, G.L., Interleukin-8 regulation of the Ras/Raf/mitogen-activated protein kinase pathway in human neutrophils. J. Biol. Chem. 271 (1996), 2832–2838.
27. [27] Murphy, C., McGurk, M., Pettigrew, J., Santinelli, A., Mazzucchelli, R., Johnston, P.G., et al. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res. 11 (2005), 4117–4127.
28. [28] Lang, K., Niggemann, B., Zanker, K.S., Entschladen, F., Signal processing in migrating T24 human bladder carcinoma cells: role of the autocrine interleukin-8 loop. Int. J. Cancer 99 (2002), 673–680.
29. [29] Kopetz, S., Shah, A.N., Gallick, G.E., Src continues aging: current and future clinical directions. Clin Cancer Res. 13 (2007), 7232–7236.
30. [30] Siesser, P.M., Hanks, S.K., The signaling and biological implications of FAK overexpression in cancer. Clin. Cancer Res. 12 (2006), 3233–3237.
31. [31] Schraufstatter, I.U., Chung, J., Burger, M., IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways. Am. J. Physiol. Lung Cell. Mol. Physiol. 280 (2001), L1094–103.
32. [32] Youn, J.I., Nagaraj, S., Collazo, M., Gabrilovich, D.I., Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181 (2008), 5791–5802.
33. [33] Poschke, I., Kiessling, R., On the armament and appearances of human myeloid-derived suppressor cells. Clin. Immunol. 144 (2012), 250–268.
34. [34] Pak, A.S., Wright, M.A., Matthews, J.P., Collins, S.L., Petruzzelli, G.J., Young, M.R., Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin. Cancer Res. 1 (1995), 95–103.
35. [35] Rodriguez, P.C., Quiceno, D.G., Zabaleta, J., Ortiz, B., Zea, A.H., Piazuelo, M.B., et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64 (2004), 5839–5849.
36. [36] Yu, J., Du, W., Yan, F., Wang, Y., Li, H., Cao, S., et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J. Immunol. 190 (2013), 3783–3797.
37. [37] Srivastava, M.K., Sinha, P., Clements, V.K., Rodriguez, P., Ostrand-Rosenberg, S., Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 70 (2010), 68–77.
38. [38] Alfaro, C., Teijeira, A., Onate, C., Perez, G., Sanmamed, M.F., Andueza, M.P., et al. Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs). Clin. Cancer Res., 2016.
39. [39] Yalavarthi, S., Gould, T.J., Rao, A.N., Mazza, L.F., Morris, A.E., Nunez-Alvarez, C., et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol. 67 (2015), 2990–3003.
40. [40] Cools-Lartigue, J., Spicer, J., McDonald, B., Gowing, S., Chow, S., Giannias, B., et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J. Clin. Invest., 2013.
41. [41] Wislez, M., Rabbe, N., Marchal, J., Milleron, B., Crestani, B., Mayaud, C., et al. Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. Cancer Res. 63 (2003), 1405–1412.
42. [42] Rao, H.L., Chen, J.W., Li, M., Xiao, Y.B., Fu, J., Zeng, Y.X., et al. Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients’ adverse prognosis. PLoS One, 7, 2012, e30806.
43. [43] Wang, J., Jia, Y., Wang, N., Zhang, X., Tan, B., Zhang, G., et al. The clinical significance of tumor-infiltrating neutrophils and neutrophil-to-CD8+ lymphocyte ratio in patients with resectable esophageal squamous cell carcinoma. J. Transl. Med., 12, 2014, 7.
44. [44] Trellakis, S., Farjah, H., Bruderek, K., Dumitru, C.A., Hoffmann, T.K., Lang, S., et al. Peripheral blood neutrophil granulocytes from patients with head and neck squamous cell carcinoma functionally differ from their counterparts in healthy donors. Int. J. Immunopathol. Pharmacol. 24 (2011), 683–693.
45. [45] Kuang, D.M., Zhao, Q., Wu, Y., Peng, C., Wang, J., Xu, Z., et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J. Hepatol. 54 (2011), 948–955.
46. [46] Jensen, T.O., Schmidt, H., Moller, H.J., Donskov, F., Hoyer, M., Sjoegren, P., et al. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 118 (2012), 2476–2485.
47. [47] Donskov, F., von der Maase, H., Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J. Clin. Oncol. 24 (2006), 1997–2005.
48. [48] Jensen, H.K., Donskov, F., Marcussen, N., Nordsmark, M., Lundbeck, F., von der Maase, H., Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J. Clin. Oncol. 27 (2009), 4709–4717.
49. [49] Fridlender, Z.G., Sun, J., Mishalian, I., Singhal, S., Cheng, G., Kapoor, V., et al. Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS One, 7, 2012, e31524.
50. [50] Hubert, P., Heitzmann, A., Viel, S., Nicolas, A., Sastre-Garau, X., Oppezzo, P., et al. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Cancer Res. 71 (2011), 5134–5143.
51. [51] Zivkovic, M., Poljak-Blazi, M., Zarkovic, K., Mihaljevic, D., Schaur, R.J., Zarkovic, N., Oxidative burst of neutrophils against melanoma B16-F10. Cancer Lett. 246 (2007), 100–108.
52. [52] Fridlender, Z.G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: N1 versus N2 TAN. Cancer Cell 16 (2009), 183–194.
53. [53] Nozawa, H., Chiu, C., Hanahan, D., Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 12493–12498.
54. [54] Sun, Z., Yang, P., Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol. 5 (2004), 182–190.
55. [55] Rotondo, R., Barisione, G., Mastracci, L., Grossi, F., Orengo, A.M., Costa, R., et al. IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. Int. J. Cancer 125 (2009), 887–893.
56. [56] Mishalian, I., Bayuh, R., Eruslanov, E., Michaeli, J., Levy, L., Zolotarov, L., et al. Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17-a new mechanism of impaired antitumor immunity. Int. J. Cancer 135 (2014), 1178–1186.
57. [57] Sparmann, A., Bar-Sagi, D., Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6 (2004), 447–458.
58. [58] Ji, H., Houghton, A.M., Mariani, T.J., Perera, S., Kim, C.B., Padera, R., et al. K-ras activation generates an inflammatory response in lung tumors. Oncogene 25 (2006), 2105–2112.
59. [59] Freisinger, C.M., Huttenlocher, A., Live imaging and gene expression analysis in zebrafish identifies a link between neutrophils and epithelial to mesenchymal transition. PLoS One, 9, 2014, e112183.
60. [60] Akalay, I., Janji, B., Hasmim, M., Noman, M.Z., Andre, F., De Cremoux, P., et al. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res. 73 (2013), 2418–2427.
61. [61] David, J.M., Dominguez, C., Hamilton, D.H., Palena, C., The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance. Vaccines (Basel), 4, 2016.
62. [62] Zuccari, D.A., Leonel, C., Castro, R., Gelaleti, G.B., Jardim, B.V., Moscheta, M.G., et al. An immunohistochemical study of interleukin-8 (IL-8) in breast cancer. Acta Histochem. 114 (2012), 571–576.
63. [63] Lin, Y., Huang, R., Chen, L., Li, S., Shi, Q., Jordan, C., et al. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int. J. Cancer 109 (2004), 507–515.
64. [64] Singh, J.K., Simoes, B.M., Clarke, R.B., Bundred, N.J., Targeting IL-8 signalling to inhibit breast cancer stem cell activity. Expert Opin. Ther. Targets 17 (2013), 1235–1241.
65. [65] Singh, J.K., Simoes, B.M., Howell, S.J., Farnie, G., Clarke, R.B., Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res., 15, 2013, 210.
66. [66] Chelouche-Lev, D., Miller, C.P., Tellez, C., Ruiz, M., Bar-Eli, M., Price, J.E., Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy. Eur. J. Cancer 40 (2004), 2509–2518.
67. [67] Marjon, P.L., Bobrovnikova-Marjon, E.V., Abcouwer, S.F., Expression of the pro-angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 by human breast carcinomas is responsive to nutrient deprivation and endoplasmic reticulum stress. Mol. Cancer, 3, 2004, 4.
68. [68] Yao, C., Lin, Y., Chua, M.S., Ye, C.S., Bi, J., Li, W., et al. Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int. J. Cancer 121 (2007), 1949–1957.
69. [69] Kerbel, R.S., Yu, J., Tran, J., Man, S., Viloria-Petit, A., Klement, G., et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 20 (2001), 79–86.
70. [70] Salcedo, R., Martins-Green, M., Gertz, B., Oppenheim, J.J., Murphy, W.J., Combined administration of antibodies to human interleukin 8 and epidermal growth factor receptor results in increased antimetastatic effects on human breast carcinoma xenografts. Clin. Cancer Res. 8 (2002), 2655–2665.
71. [71] De Larco, J.E., Wuertz, B.R., Rosner, K.A., Erickson, S.A., Gamache, D.E., Manivel, J.C., et al. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am. J. Pathol. 158 (2001), 639–646.
72. [72] De Larco, J.E., Wuertz, B.R., Yee, D., Rickert, B.L., Furcht, L.T., Atypical methylation of the interleukin-8 gene correlates strongly with the metastatic potential of breast carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 13988–13993.
73. [73] Singh, B., Berry, J.A., Vincent, L.E., Lucci, A., Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer. J. Surg. Res. 134 (2006), 44–51.
74. [74] Wu, K., Katiyar, S., Li, A., Liu, M., Ju, X., Popov, V.M., et al. Dachshund inhibits oncogene-induced breast cancer cellular migration and invasion through suppression of interleukin-8. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 6924–6929.
75. [75] Benoy, I.H., Salgado, R., Van Dam, P., Geboers, K., Van Marck, E., Scharpe, S., et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin. Cancer Res. 10 (2004), 7157–7162.
76. [76] Milovanovic, J., Todorovic-Rakovic, N., Abu Rabi, Z., The prognostic role of interleukin-8 (IL-8) and matrix metalloproteinases −2 and −9 in lymph node-negative untreated breast cancer patients. J. Buon. 18 (2013), 866–873.
77. [77] Snoussi, K., Mahfoudh, W., Bouaouina, N., Fekih, M., Khairi, H., Helal, A.N., et al. Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness. BMC Cancer, 10, 2010, 283.
78. [78] Huang, Q., Wang, C., Qiu, L.J., Shao, F., Yu, J.H., IL-8-251A > T polymorphism is associated with breast cancer risk: a meta-analysis. J. Cancer Res. Clin. Oncol. 137 (2011), 1147–1150.
79. [79] Singh, R.K., Lokeshwar, B.L., The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res. 71 (2011), 3268–3277.
80. [80] Zhang, T., Tseng, C., Zhang, Y., Sirin, O., Corn, P.G., Li-Ning-Tapia, E.M., et al. CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nat. Commun., 7, 2016, 11674.
81. [81] Zhao, H., Dupont, J., Yakar, S., Karas, M., LeRoith, D., PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 23 (2004), 786–794.
82. [82] Maxwell, P.J., Coulter, J., Walker, S.M., McKechnie, M., Neisen, J., McCabe, N., et al. Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma. Eur. Urol. 64 (2013), 177–188.
83. [83] Armstrong, C.W., Maxwell, P.J., Ong, C.W., Redmond, K.M., McCann, C., Neisen, J., et al. PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy. Oncotarget, 2016.
84. [84] Chen, K., Wu, K., Jiao, X., Wang, L., Ju, X., Wang, M., et al. The endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a cxcl signaling module. Cancer Res. 75 (2015), 1992–2004.
85. [85] Uehara, H., Troncoso, P., Johnston, D., Bucana, C.D., Dinney, C., Dong, Z., et al. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate 64 (2005), 40–49.
86. [86] Veltri, R.W., Miller, M.C., Zhao, G., Ng, A., Marley, G.M., Wright, G.L. Jr., et al. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology 53 (1999), 139–147.
87. [87] Smith, D.R., Polverini, P.J., Kunkel, S.L., Orringer, M.B., Whyte, R.I., Burdick, M.D., et al. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J. Exp. Med. 179 (1994), 1409–1415.
88. [88] Arenberg, D.A., Kunkel, S.L., Polverini, P.J., Glass, M., Burdick, M.D., Strieter, R.M., Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J. Clin. Invest. 97 (1996), 2792–2802.
89. [89] Li, X., Wang, S., Zhu, R., Li, H., Han, Q., Zhao, R.C., Lung tumor exosomes induce a pro-inflammatory phenotype in mesenchymal stem cells via NFkappaB-TLR signaling pathway. J. Hematol. Oncol., 9, 2016, 42.
90. [90] Masuya, D., Huang, C., Liu, D., Kameyama, K., Hayashi, E., Yamauchi, A., et al. The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer 92 (2001), 2628–2638.
91. [91] Desai, S., Laskar, S., Pandey, B.N., Autocrine IL-8 and VEGF mediate epithelial-mesenchymal transition and invasiveness via p38/JNK-ATF-2 signalling in A549 lung cancer cells. Cell Signal. 25 (2013), 1780–1791.
92. [92] Bendre, M.S., Margulies, A.G., Walser, B., Akel, N.S., Bhattacharrya, S., Skinner, R.A., et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res. 65 (2005), 11001–11009.
93. [93] Hsu, Y.L., Hung, J.Y., Ko, Y.C., Hung, C.H., Huang, M.S., Kuo, P.L., Phospholipase, D., signaling pathway is involved in lung cancer-derived IL-8 increased osteoclastogenesis. Carcinogenesis 31 (2010), 587–596.
94. [94] Lagiou, P., Trichopoulos, D., Inflammatory biomarkers and risk of lung cancer. J. Natl. Cancer Inst. 103 (2011), 1073–1075.
95. [95] Yuan, A., Yu, C.J., Luh, K.T., Kuo, S.H., Lee, Y.C., Yang, P.C., Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J. Clin. Oncol. 20 (2002), 900–910.
96. [96] Sunaga, N., Kaira, K., Tomizawa, Y., Shimizu, K., Imai, H., Takahashi, G., et al. Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma. Br. J. Cancer 110 (2014), 2047–2053.
97. [97] Tas, F., Duranyildiz, D., Oguz, H., Camlica, H., Yasasever, V., Topuz, E., Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer. Cancer Invest. 24 (2006), 492–496.
98. [98] Singh, R.K., Varney, M.L., Regulation of interleukin 8 expression in human malignant melanoma cells. Cancer Res. 58 (1998), 1532–1537.
99. [99] Luca, M., Huang, S., Gershenwald, J.E., Singh, R.K., Reich, R., Bar-Eli, M., Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am. J. Pathol. 151 (1997), 1105–1113.
100. [100] Kunz, M., Hartmann, A., Flory, E., Toksoy, A., Koczan, D., Thiesen, H.J., et al. Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma: a potential mechanism for high tumor aggressiveness. Am. J. Pathol. 155 (1999), 753–763.
101. [101] Uen, W.C., Hsieh, C.H., Tseng, T.T., Jiang, S.S., Tseng, J.C., Lee, S.C., Anchorage independency promoted tumor malignancy of melanoma cells under reattachment through elevated interleukin-8 and CXC chemokine receptor 1 expression. Melanoma Res. 25 (2015), 35–46.
102. [102] Scheibenbogen, C., Mohler, T., Haefele, J., Hunstein, W., Keilholz, U., Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res. 5 (1995), 179–181.
103. [103] Ramjeesingh, R., Leung, R., Siu, C.H., Interleukin-8 secreted by endothelial cells induces chemotaxis of melanoma cells through the chemokine receptor CXCR1. FASEB J. 17 (2003), 1292–1294.
104. [104] Singh, S., Varney, M., Singh, R.K., Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res. 69 (2009), 411–415.
105. [105] Gabellini, C., Trisciuoglio, D., Desideri, M., Candiloro, A., Ragazzoni, Y., Orlandi, A., et al. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. Eur. J. Cancer 45 (2009), 2618–2627.
106. [106] Lattanzio, L., Tonissi, F., Torta, I., Gianello, L., Russi, E., Milano, G., et al. Role of IL-8 induced angiogenesis in uveal melanoma. Invest. New Drugs. 31 (2013), 1107–1114.
107. [107] Brew, R., Erikson, J.S., West, D.C., Kinsella, A.R., Slavin, J., Christmas, S.E., Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine 12 (2000), 78–85.
108. [108] Xiao, Y.C., Yang, Z.B., Cheng, X.S., Fang, X.B., Shen, T., Xia, C.F., et al. CXCL8, overexpressed in colorectal cancer, enhances the resistance of colorectal cancer cells to anoikis. Cancer Lett. 361 (2015), 22–32.
109. [109] Konig, B., Steinbach, F., Janocha, B., Drynda, A., Stumm, M., Philipp, C., et al. The differential expression of proinflammatory cytokines IL-6, IL-8 and TNF-alpha in renal cell carcinoma. Anticancer Res. 19 (1999), 1519–1524.
110. [110] Kamohara, H., Takahashi, M., Ishiko, T., Ogawa, M., Baba, H., Induction of interleukin-8 (CXCL-8) by tumor necrosis factor-alpha and leukemia inhibitory factor in pancreatic carcinoma cells: impact of CXCL-8 as an autocrine growth factor. Int. J. Oncol. 31 (2007), 627–632.
111. [111] Yoshida, M., Matsuzaki, H., Sakata, K., Takeya, M., Kato, K., Mizushima, S., et al. Neutrophil chemotactic factors produced by a cell line from thyroid carcinoma. Cancer Res. 52 (1992), 464–469.
112. [112] Weetman, A.P., Bennett, G.L., Wong, W.L., Thyroid follicular cells produce interleukin-8. J. Clin. Endocrinol. Metab. 75 (1992), 328–330.
113. [113] Yasumoto, K., Okamoto, S., Mukaida, N., Murakami, S., Mai, M., Matsushima, K., Tumor necrosis factor alpha and interferon gamma synergistically induce interleukin 8 production in a human gastric cancer cell line through acting concurrently on AP-1 and NF-kB-like binding sites of the interleukin 8 gene. J. Biol. Chem. 267 (1992), 22506–22511.
114. [114] Kitadai, Y., Haruma, K., Sumii, K., Yamamoto, S., Ue, T., Yokozaki, H., et al. Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am. J. Pathol. 152 (1998), 93–100.
115. [115] Kitadai, Y., Takahashi, Y., Haruma, K., Naka, K., Sumii, K., Yokozaki, H., et al. Transfection of interleukin-8 increases angiogenesis and tumorigenesis of human gastric carcinoma cells in nude mice. Br. J. Cancer 81 (1999), 647–653.
116. [116] Lee, L.F., Hellendall, R.P., Wang, Y., Haskill, J.S., Mukaida, N., Matsushima, K., et al. IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J. Immunol. 164 (2000), 2769–2775.
117. [117] Isaza-Correa, J.M., Liang, Z., van den Berg, A., Diepstra, A., Visser, L., Toll-like receptors in the pathogenesis of human B cell malignancies. J. Hematol. Oncol., 7, 2014, 57.
118. [118] Schonbohn, H., Schuler, M., Kolbe, K., Peschel, C., Huber, C., Bemb, W., et al. Plasma levels of IL-1, TNF alpha, IL-6, IL-8, G-CSF, and IL1-RA during febrile neutropenia: results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemia. Ann. Hematol. 71 (1995), 161–168.
119. [119] di Celle, P.F., Carbone, A., Marchis, D., Zhou, D., Sozzani, S., Zupo, S., et al. Cytokine gene expression in B-cell chronic lymphocytic leukemia: evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein. Blood 84 (1994), 220–228.
120. [120] Gruss, H.J., Brach, M.A., Drexler, H.G., Bonifer, R., Mertelsmann, R.H., Herrmann, F., Expression of cytokine genes, cytokine receptor genes, and transcription factors in cultured Hodgkin and Reed-Sternberg cells. Cancer Res. 52 (1992), 3353–3360.
121. [121] Ning, Y., Manegold, P.C., Hong, Y.K., Zhang, W., Pohl, A., Lurje, G., et al. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int. J. Cancer 128 (2011), 2038–2049.
122. [122] Ueda, T., Shimada, E., Urakawa, T., Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J. Gastroenterol. 29 (1994), 423–429.
123. [123] Dimberg, J., Strom, K., Lofgren, S., Zar, N., Lindh, M., Matussek, A., DNA promoter methylation status and protein expression of interleukin-8 in human colorectal adenocarcinomas. Int. J. Colorectal. Dis. 27 (2012), 709–714.
124. [124] Rubie, C., Frick, V.O., Pfeil, S., Wagner, M., Kollmar, O., Kopp, B., et al. Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer. World J. Gastroenterol. 13 (2007), 4996–5002.
125. [125] Bi, L.K., Zhou, N., Liu, C., Lu, F.D., Lin, T.X., Xuan, X.J., et al. Kidney cancer cells secrete IL-8 to activate Akt and promote migration of mesenchymal stem cells. Urol. Oncol. 32 (2014), 607–612.
126. [126] Huang, D., Ding, Y., Zhou, M., Rini, B.I., Petillo, D., Qian, C.N., et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 70 (2010), 1063–1071.
127. [127] Casilli, F., Bianchini, A., Gloaguen, I., Biordi, L., Alesse, E., Festuccia, C., et al. Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2. Biochem. Pharmacol. 69 (2005), 385–394.
128. [128] Ginestier, C., Liu, S., Diebel, M.E., Korkaya, H., Luo, M., Brown, M., et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest. 120 (2010), 485–497.
129. [129] Brandolini, L., Cristiano, L., Fidoamore, A., De Pizzol, M., Di Giacomo, E., Florio, T.M., et al. Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling. Oncotarget 6 (2015), 43375–43394.
130. [130] Ning, Y., Labonte, M.J., Zhang, W., Bohanes, P.O., Gerger, A., Yang, D., et al. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Mol. Cancer Ther. 11 (2012), 1353–1364.
131. [131] Singh, S., Sadanandam, A., Nannuru, K.C., Varney, M.L., Mayer-Ezell, R., Bond, R., et al. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin Cancer Res. 15 (2009), 2380–2386.
132. [132] Varney, M.L., Singh, S., Li, A., Mayer-Ezell, R., Bond, R., Singh, R.K., Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases. Cancer Lett. 300 (2011), 180–188.
133. [133] Singh, J.K., Farnie, G., Bundred, N.J., Simoes, B.M., Shergill, A., Landberg, G., et al. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and −independent mechanisms. Clin. Cancer Res. 19 (2013), 643–656.
134. [134] Liu, X., Peng, J., Sun, W., Yang, S., Deng, G., Li, F., et al. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice. Tohoku J. Exp. Med. 228 (2012), 147–156.
135. [135] Mian, B.M., Dinney, C.P., Bermejo, C.E., Sweeney, P., Tellez, C., Yang, X.D., et al. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin. Cancer Res. 9 (2003), 3167–3175.
136. [136] Huang, S., Mills, L., Mian, B., Tellez, C., McCarty, M., Yang, X.D., et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am. J. Pathol. 161 (2002), 125–134.
137. [137] Shao, N., Chen, L.H., Ye, R.Y., Lin, Y., Wang, S.M., The depletion of interleukin-8 causes cell cycle arrest and increases the efficacy of docetaxel in breast cancer cells. Biochem. Biophys. Res. Commun. 431 (2013), 535–541.
138. [138] Kamalakar, A., Bendre, M.S., Washam, C.L., Fowler, T.W., Carver, A., Dilley, J.D., et al. Circulating interleukin-8 levels explain breast cancer osteolysis in mice and humans. Bone 61 (2014), 176–185.
139. [139] Seaton, A., Scullin, P., Maxwell, P.J., Wilson, C., Pettigrew, J., Gallagher, R., et al. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis 29 (2008), 1148–1156.
140. [140] Chen, H., Sun, Y., Wu, C., Magyar, C.E., Li, X., Cheng, L., et al. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr. Relat. Cancer 19 (2012), 321–331.
141. [141] Inoue, K., Slaton, J.W., Eve, B.Y., Kim, S.J., Perrotte, P., Balbay, M.D., et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res. 6 (2000), 2104–2119.
142. [142] Singh, R.K., Lokeshwar, B.L., Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol. Cancer, 8, 2009, 57.
143. [143] Pold, M., Zhu, L.X., Sharma, S., Burdick, M.D., Lin, Y., Lee, P.P., et al. Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res. 64 (2004), 1853–1860.
144. [144] Boldrini, L., Gisfredi, S., Ursino, S., Lucchi, M., Mussi, A., Basolo, F., et al. Interleukin-8 in non-small cell lung carcinoma: relation with angiogenic pattern and p53 alterations. Lung Cancer 50 (2005), 309–317.
145. [145] Iguchi, H., Ono, M., Matsushima, K., Kuwano, M., Overproduction of IL-8 results in suppression of bone metastasis by lung cancer cells in vivo. Int. J. Oncol. 17 (2000), 329–333.
146. [146] Shiau, M.Y., Fan, L.C., Yang, S.C., Tsao, C.H., Lee, H., Cheng, Y.W., et al. Human papillomavirus up-regulates MMP-2 and MMP-9 expression and activity by inducing interleukin-8 in lung adenocarcinomas. PLoS One, 8, 2013, e54423.
147. [147] Brew, R., Erikson, J.S., West, D.C., Flanagan, B.F., Christmas, S.E., Interleukin-8 as a growth factor for human colorectal carcinoma cells in vitro. Biochem. Soc. Trans., 25, 1997, 264s.
148. [148] Itoh, Y., Joh, T., Tanida, S., Sasaki, M., Kataoka, H., Itoh, K., et al. IL-8 promotes cell proliferation and migration through metalloproteinase-cleavage proHB-EGF in human colon carcinoma cells. Cytokine 29 (2005), 275–282.
149. [149] Cheng, X.S., Li, Y.F., Tan, J., Sun, B., Xiao, Y.C., Fang, X.B., et al. CCL20 and CXCL8 synergize to promote progression and poor survival outcome in patients with colorectal cancer by collaborative induction of the epithelial-mesenchymal transition. Cancer Lett. 348 (2014), 77–87.
150. [150] Sun, Q., Sun, F., Wang, B., Liu, S., Niu, W., Liu, E., et al. Interleukin-8 promotes cell migration through integrin alphavbeta6 upregulation in colorectal cancer. Cancer Lett. 354 (2014), 245–253.
151. [151] Wilson, C., Purcell, C., Seaton, A., Oladipo, O., Maxwell, P.J., O'Sullivan, J.M., et al. Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J. Pharmacol. Exp. Ther. 327 (2008), 746–759.
152. [152] Dabkeviciene, D., Jonusiene, V., Zitkute, V., Zalyte, E., Grigaitis, P., Kirveliene, V., et al. The role of interleukin-8 (CXCL8) and CXCR2 in acquired chemoresistance of human colorectal carcinoma cells HCT116. Med. Oncol., 32, 2015, 258.
153. [153] Li, A., Varney, M.L., Valasek, J., Godfrey, M., Dave, B.J., Singh, R.K., Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis 8 (2005), 63–71.
154. [154] van Hinsbergh, V.W., Koolwijk, P., Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc. Res. 78 (2008), 203–212.
155. [155] Biasini, M., Bienert, S., Waterhouse, A., Arnold, K., Studer, G., Schmidt, T., et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res. 42 (2014), W252–W258.